Current Status of Activation Markers in lschemic Heart Disease: Markers of Coagulation Activation

• References

• 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute ischemic syndromes. New Engl J Med 1992; 326: 242-250
• 2 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute ischemic syndromes. New Engl J Med 1992; 326: 310-318
• 3 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation. Blood 1987; 70 (02) 343-350
• 4 van Hulsteijn H, Kolff J, Briet E, van der LaarseA, Bertina R. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. Am Heart J 1984; 107: 39-45
• 5 Neri SerneriGG, Gensini GF, Abbate R, Laureano R, Parodi O. Is raised plasma fibrinopeptide A a marker of acute coronary insufficiency. Lancet 1980; 02: 982
• 6 Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985; 71: 912-918
• 7 Theroux P, Latour JG, Leger-Gautier C, De Lara J. Fibrinopeptide A plasma levels and platelet factor 4 levels in unstable angina pectoris. Circulation 1987; 75: 156-162
• 8 Merlini PA, BauerK A, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68
• 9 Eisenberg PR, Kenzora JL, Sobel BE, Ludbrook PA, Jaffe AS. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. J Am Coll Cardiol 1991; 18: 898-903
• 10 Mizuno K, Satumora K, Miyamoto A, Arakawa E, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose J. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287
• 11 Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PA. Thrombogenic potential of human atherosclerotic plaques. Lancet 1997; 349: 769-771
• 12 Ardissino D, Gamba MG, Merlini PA, Rolla A, Barberis P, Demicheli G, Testa S, Bruno N, Specchia G. Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina pectoris. Am J Cardiol 68: 58B-63B 1991;
• 13 Wilenski R, Bourdillon PDV, Vix VA, Zeller JA. Intracoronary artery thrombus formation in unstable abgina: a clinical, biochemical and angiographic correlation. J Am Coll Cardiol 1993; 21: 692-699
• 14 Mombelli G, Hof I, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984; 69: 684-689
• 15 Gallino A, Haeberli A, Hess T, Mombelli G, Straub PW. Fibrin formation and platelet aggregation in patients with acute myocardial infarction:effect of intravenous and subcutaneous low-dose heparin. Am Heart J 1986; 112: 285-290
• 16 Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-151
• 17 Merlini PA, Ardissino D, Bauer KA, Oltrona L, Bottasso B, Pezzano A, Rosenberg RD, Mannucci PM. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. AtherosclerosisThrombosis Vasc Biol. 1997 (in press)
• 18 Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90: 2671-2678
• 19 Zoldhelyi P, Bichler J, Owen WG, McBane RM, Hassinger N, Gaspar D, Chesebro JH. Measurement of thrombin-hirudin complex documents persistent thrombin formation in patients with unstable angina during anticoagulation with recombinant hirudin. Circulation 1993; 88: 1-319 (abs)
• 20 Nesheim ME, Mann KG. Thrombin catalyzed activation of single-chain bovine factor V. J Biol Chem 1979; 254: 1326-1334
• 21 Hoyer LW, Trabold NC. Effect of thrombin on human factor VIII: cleavage of the factor VIII procoagulant protein during activation. J Lab Clin Med 1989; 97: 50-64
• 22 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-1024
• 23 Granger CB, Miller JM, Bovill E, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf R. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-1935
• 24 Gold HK, Torres FW, garabendian HD, Werner W, Jang I, Khan A, Hagstrom JN, Yasuda T, Lainbach RC, Newell JB, Bovill E, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21: 1039-1047
• 25 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induced transient thrombin activity. Blood 1988; 72: 616-620
• 26 Eisenberg PR, Sherman LA, Jaffe AD. Paradoxicelevationof fibrinopeptide A after streptokinase: evidence for continued thrombosis despite fibrinolysis. J Am Coll Cardiol 1987; 10: 527-529
• 27 Gulba DC, Barthels M, Westhoff-Bleck M. et al: Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991; 83: 937-944
• 28 Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 19: 1065-1069
• 29 Baglin TP, Luddington R, Jennings I, Richards EM. Thrombin generation and myocardial infarction during infusion of tissueplasminogen activator. The Lancet 1993; 01: 505
• 30 Genser N, Mair J, Maier J, Dienstl F, Puschendorf B, Lechleitner P. Thrombin generation during infusion of tissue-type plasminogen activator. Lancet 1993; 01: 1038
• 31 Merlini PA, Cattaneo M, Spinola A. et al: Activation of the hemostatic system during thrombolytic therapy. Am J Cardiol 1993; 72: 59G-65G
• 32 Rapold HJ, deBono D, Arnold AER. et al Plasma fibrinopeptide A levels in patients with myocardial infarction treated with alteplase. Circulation 1992; 85: 928-934
• 33 Merlini PA, Bauer K, Oltrona L. et al: Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25: 203
• 34 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithromin complex. J Clin Invest 1983; 71: 1383-1391
• 35 Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73: 185-190
• 36 The TIMI IIIB Investigators. Effect of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation 1994; 89: 1545-1556
• 37 Merlini PA, Ardissino D, Bauer K, Oltrona L, Spinola A, Diotallevi P, Rosenberg RD, Mannucci PM. Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Blood 1995; 86: 3327-3332
• 38 Ardissino D, Merlini PA, Gamba G, Barberis P, Demicheli G, Testa S, Colombi E, Poli A, Fetiveau R, Montemartini C. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996; 93: 1634-1639
• 39 Granger CB, Becker R, Tracy RP, califf RM, Topol EJ, Pieper KS, Ross AM, Roth SR, Lambrew C, Bovill EG. for the GUSTO Hemostasis Substudy Group Thrombin generation, inhibition, and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO trial. J Am Coll Cardioll. 1997 (in press)
• 40 Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996; 94: 2064-2071